DNAprint Genomics (DNAG)

[worktoplay]

Have you ever looked at the similarities in the following language:

Until recently, to explain or solve the problem of differential drug response, for example, it has been necessary to perform pan-genome screening, but one cannot explain the genomic basis for these traits simply by screening genomes with randomly selected or publicly available markers. Our competitors do this - they select a small number of SNPs in a small number of genes (called a "Candidate gene" approach) in an attempt to study extreme responder and non-responder phenotypes. If they pick the wrong SNPs or genes, they do not find a solution - this is the problem with the traditional research approach used by most companies.

Another approach is to look at the entire genome. Genome based linkage analysis in large populations of unrelated individuals is not cost effective since it costs hundreds of thousands of dollars per patient to do this type of study properly. Other companies use "isolated populations" to bring the costs down, but this approach carries significant disadvantages because their results do not necessarily generalize to other populations.

And:

To solve these traits, it is necessary to perform pan-genome screening, but one cannot solve these traits simply by screening genomes with randomly selected or publicly available markers. Our competitors do this - they select a small number of SNPs in a small number of genes (called a "Candidate gene" approach) in an attempt to study extreme responder and non-responder phenotypes. If they pick the wrong SNPs or genes, they do not find a solution - this is the problem with the hypothesis-driven approach.

Genome based linkage analysis in large populations of unrelated individuals is not cost effective because it costs several hundreds of thousands of dollars per patient to do this type of study properly. Some companies use "isolated populations" to bring the costs down, but this approach carries significant disadvantages because their results do not always generalize to the world population.

One is from the DNAPhenomics "Methods of Discovery" page, the other from the DNAP Executive Summary in their investor packet.

Incredibly similar, don't you think?

Later,
W2P